Progenics Pharmaceuticals (PGNX, $9.18, up $0.75)
The FDA granted the approval of Azedra injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland. More specifically known as pheochromocytoma or paraganglioma, adrenal glands cannot be surgically removed after spreading beyond the original tumor site and require systemic anticancer therapy.
This is the first FDA-approved drug for this use, the FDA noted. As it is a radioactive therapeutic agent, Azedra includes a warning about radiation exposure to patients and family members, which should be minimized while the patient is receiving Azedra.